Bitwise's BSOL ETF is dominating the US Solana ETF market, capturing 81% of daily inflows ($21.6 million out of $26.57 million) and 78% of year-to-date inflows (roughly $1 billion). Its appeal stems from offering direct SOL exposure with staking rewards, which institutions prefer due to regulatory compliance, simpler custody, and tax reporting. This trend suggests strong and sustained institutional demand for Solana.

Nvidia CEO Jensen Huang and his wife Lori's foundation is donating $108.3 million worth of computing time from CoreWeave to universities and other nonprofit institutes for science and AI research. This initiative includes free engineering services from Nvidia for some grant recipients. The donation also highlights Nvidia's continued support for CoreWeave, a cloud computing company specializing in AI applications, following Nvidia's previous investment and a $6.3 billion deal for cloud computing capacity.

Camtek Ltd (CAMT) shares recently dropped 3.3% to $168.88, yet the stock is considered significantly overvalued according to GuruFocus' GF Value, which estimates its fair value at $102.70. Despite the overvaluation and historical P/E ratios being much higher than its 5-year median, CAMT boasts an impressive GF Score of 90/100, driven by strong growth and profitability ratings. There have been no insider transactions reported in the last three months, suggesting a cautious stance or confidence among executives.

B93.7 is hosting a contest for a $250 gift card to Bob's Discount Furniture to celebrate the grand opening of their new Spartanburg showroom. The grand opening will take place from May 22nd to May 24th, with B9.37's Torry on-site on Sunday, May 24th. In addition to the contest, Bob's will donate $2,500 to a local nonprofit and school.

Intuitive Surgical (ISRG) is facing new investment challenges due to an FDA Class I recall on da Vinci stapler components and significant institutional selling. While the company continues to see growth in system installations and procedure volumes, these issues introduce fresh concerns about product safety and increased regulatory scrutiny. This situation prompts a re-evaluation of Investing in Intuitive Surgical (ISRG), emphasizing the need for investors to weigh operational momentum against rising risk perceptions.

Citigroup plans to increase its prime brokerage staff in the Asia-Pacific region by approximately 10% in 2024. This expansion is focused on Singapore and India, with new hires in front-office and technology roles, as part of a strategy to attract more business from regional hedge funds.

The article discusses how Schwab Corporation is gaining renewed attention due to unusual options trading activity, strong operating updates, and consistent dividends. It highlights the company's earnings momentum, platform scale, client assets, and digital asset expansion plans as key drivers supporting its business narrative and growth.

Benchmark Electronics Inc (BHE) shares rose 3.2% to $86.07, marking a 135.3% increase over the past year. Despite this performance, GuruFocus's GF Value rates BHE as "Significantly Overvalued" at $40.62, with a GF Score of 68/100. Insider activity shows $3.1 million in sales and no purchases over the last three months, signaling potential caution for investors due to the high valuation.

This article focuses solely on the number of shareholders for Princeton Bancorp, Inc. (NASDAQ: BPRN). It provides a high-level overview of the company's stock information, along with links to financial data and news, but does not present the actual number of shareholders. The page appears to be a stub or a placeholder for detailed shareholder data that has not yet been populated.

BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for encaleret to treat autosomal dominant hypocalcemia type 1 (ADH1) following successful Phase 3 trial results. The drug demonstrated rapid and sustained normalization of calcium metabolism in patients and a favorable safety profile. With a "Buy" rating from analysts and a $101.00 price target, encaleret is poised to be the first approved therapy for ADH1, with potential for expansion into pediatric ADH1 and chronic hypoparathyroidism.